RxDoctor Payments Data

Chris Wu, MD

Retina Specialist · Las Vegas, NVNPI 1265829345

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,860 of the $11,164 with a category attached, or 61.4%. Genentech USA, Inc. accounts for 74.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $8,760 and has fallen 96.0% since, to $346 in 2025.

$11,164in general payments, 2019–2025

Across 68 payments — averaging $164.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$8K
  • Alcon$1K
  • Regeneron Healthcare Solutions, Inc.$483
  • Alimera Sciences, Inc.$289
  • AbbVie$271
  • Eyepoint US, Inc.$270
  • plus $513 from 7 others

What the payments were for

  • Consulting fees$6,86061%
  • Travel & lodging$1,43213%
  • Food & beverage$2,83125%
  • Education$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,953,881
Medicare patients
1,075
Services billed
20,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab21$251,080
Prednisolone Acetate160$6,667
ProlensaBromfenac Sodium11$6,382
Bromfenac Sodium55$6,381
Brimonidine Tartrate46$3,455
SimbrinzaBrinzolamide/Brimonidine Tart12$2,382
Difluprednate15$2,128
ValacyclovirValacyclovir Hcl24$889
Ketorolac Tromethamine51$866
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat40$765
Mycophenolate Mofetil12$719
MoxifloxacinMoxifloxacin Hcl23$543
Prednisone28$316
Latanoprost34$281
ErythromycinErythromycin Base12$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$1,042$2,38212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other retina specialist in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →